{
  "docId": "019de075-cd17-7685-9273-fb1c731af40f",
  "docSlug": "16b2d7592f4634ac7cd717a996934f07",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 35 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 35,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "valuation_table",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 24,
  "notes": "The table displays projected royalties, net sales, and milestone payments from 2023 to 2026.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-cd17-7685-9273-fb1c731af40f/24",
  "deckHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f",
  "deckJsonHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f.json",
  "deckAnchorHref": "/decks/019de075-cd17-7685-9273-fb1c731af40f#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.15,
        "y": 0.2
      },
      "kind": "callout",
      "text": "Mid-Term Value",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fe4038a-3ee2-44df-9ed2-04a763a77244",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.64,
        "y": 0.2
      },
      "kind": "callout",
      "text": "Long-Term Value",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d5d90629-7223-49ef-8d36-0c477dbd7aba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.6,
        "y": 0.42
      },
      "kind": "list",
      "text": "Ex-US royalties return Jul. 1, 2029; US royalties return after Jan. 1, 2031; Paid directly from Royalty Pharma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc33a90a-b62d-469a-a26d-403508c2018c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.04,
        "y": 0.8
      },
      "kind": "metric",
      "text": "Q2'23 Net Sales of $760M | YTD Net Sales of $1.33B",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0919696b-c8a8-45b9-9338-853e59fdaa76",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.85,
        "x": 0.14,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. If both milestones are achieved in a given year, Theravance Biopharma will only earn the higher milestone. 2. Based on 100% of TRELEGY ELLIPTA royalties. 3. 85% of TRELEGY ELLIPTA royalties return to Theravance Biopharma beginning July 1, 2029 for sales ex-U.S., and January 1, 2031 for sales within the U.S.; U.S. royalties expected to end late 2032; ex-U.S. royalties expected to end mid-2030s and are country specific. 4. Source: GSK-reported Net Sales in USD.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9753a127-0b54-4fe0-a740-2d2b9f7be7ae",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.9,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "subtitle",
      "text": "GSK's TRELEGY ELLIPTA (FF/UMEC/VI): First and only once-daily single inhaler triple therapy",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a6790df5-17c2-47b1-8852-7d144d129888",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.42,
        "x": 0.09,
        "y": 0.39
      },
      "kind": "table",
      "text": "Year, Royalties, Global Net Sales Equivalent, Milestone",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1fb13230-0742-4dcd-97cc-603a37bd2c19",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.65,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "TRELEGY ELLIPTA Milestones and Royalties",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "051d3567-029c-44de-b2ca-a697110b2030",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 25,
      "from": 19,
      "beatId": "94e3fc43-5901-462d-839a-07bb0f06e654",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The document outlines the company's financial update and expected milestones",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}